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Development of a RadFET Linear Array for
Intracavitary in vivo Dosimetry During External
Beam Radiotherapy and Brachytherapy
Robert A. Price*, Member, IEEE, Chris Benson, Malcolm J. Joyce, and Kenneth Rodgers
Abstract—We present the details of a new linear array
dosimeter consisting of a chain of semiconductors mounted on
an ultra-thin (50 m thick) flexible substrate and housed in
an intracavitary catheter. The semiconductors, manufactured
by NMRC Cork, have not been packaging and incorporate a
passivation layer that allows them to be mounted on the substrate
using flip-chip-bonding. This paper reports, for the first time, the
construction of a multiple (ten) detector array suited to in vivo
dosimetry in the rectum, esophagus and vagina during external
beam radiotherapy, as well as being adaptable to in vivo dosimetry
during brachytherapy and diagnostic radiology.
Index Terms—Dosimetry, in vivo patient dosimetry, MOSFET,
RadFET, radiotherapy, semiconductor detectors.
I. INTRODUCTION
THE overall process of planning and treatment of a patientwith ionizing radiation encompasses many complex and
diverse steps, all of which are subject to uncertainty [1] and pos-
sible human error. In order to provide efficacious disease man-
agement, radiotherapy treatment requires the patient to be ac-
curately positioned with respect to the radiation fields so that
a therapeutic dose can be delivered to the target region (tumor)
whilst the absorbed dose to the normal tissue and organs at risk
is kept to a minimum. It is known that the accuracy with which
the patient is positioned in the beam affects both the probability
of cure (tumor control) and the undesirable complication rate
[2]. In addition to the geometric precision with which the pa-
tient is positioned, the efficacy of the treatment is critically de-
pendent on the magnitude of the absorbed dose in the tumor
and other volumes. Using clinically derived dose-effect curves
for local tumor-control and normal tissue-complications, var-
ious authors have estimated the accuracy requirements for dose
delivery in conventional external-beam treatments to be 3.5%
for absolute dose at the specification point and 5% at other
points within the target volume [3]–[6]. For other, high-pre-
cision treatments such as conformal radiotherapy, Essers [7]
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notes that the accuracy criteria may need to be tightened: cur-
rent wisdom stating a 2% or 2 mm criterion on absorbed dose
and positional accuracy respectively.
It is apparent that effective quality assurance and control pro-
cedures are essential in radiotherapy if the above stated accu-
racy is to be achieved and maintained. Within such a quality as-
surance program, individual quality control tasks are concerned
with checking the accuracy and precision of each step in the
planning and delivery chain [8] but it is only at the final step,
when a beam is actually delivered to a patient, that a single check
on the whole procedure (through in vivo dosimetry measure-
ments) can be made and the attainment of a desired dose-accu-
racy formally confirmed.
Clearly, patient dose verification at the point of delivery is
an important part of quality assurance in radiotherapy treat-
ment [9]. It is included as a requirement in the UK Manual of
Cancer Standards [10] and is recommended within the whole of
Europe [11] and North America [12] for procedures involving
high doses to the patient. When included as part of a general
system of radiotherapy quality assurance within a clinic, in vivo
dosimetry can significantly reduce the risk of mistreatment. Two
commonly used detectors for in vivo dosimetry are thermolumi-
nescence dosimeters (TLDs) and semiconductors.
TLDs are popular because of their small size but they require
extremely careful handling and calibration in order to obtain a
measurement accuracy of better than 5% at 95% confidence.
They are, to some degree, inconvenient to use, as they require
specialized ovens for post irradiation annealing and expensive
TLD reading equipment. Further, they do not provide a means
of ‘real-time’ dosimetry because there must be a well-controlled
delay of approximately two hours or more between irradiation
and reading in order to allow the decay of short-lived traps. Due
to the stringent handling requirements and the need to protect
the TLD chips from UV light and chemical contaminants they
are not well-suited for inclusion in arrays or for use in intracav-
itary dosimetry. Some authors have, however, used TLDs for
intracavitary in vivo dosimetry—for example, Brezovich [13],
et al. incorporated some 20 LiF rods in a 6fr urethral catheter
in order to verify high dose rate (HDR) prostrate treatments; the
TLD rods being read within 24–48 hrs of the radiation treatment.
Semiconductor detectors such as diodes and metal-oxide
field-effect transistors [14] (MOSFETs) provide a conve-
nient alternative to TLD technology. Such detectors can be
constructed with a small active volume whilst retaining high
sensitivity and accuracy [15]. Importantly, real-time in vivo
dosimetry (using semiconductor detectors, MOSFETs or dia-
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monds, etc) allows differences in recorded and expected dose
values to be investigated with the patient still in the treatment
position [16]. Based on such measurements and an analysis
of the actual treatment set-up, a treatment can be modified, if
deemed suitable, before the next fraction in order to bring the
overall treatment back in-line with expectations. This approach
to the use of real-time in vivo dosimetry is discussed by several
authors [17], [18] and has been put into practical use by various
groups [19]–[21].
The majority of in vivo dosimetric measurements performed
in the clinic are achieved by placing the detector on the entrance
or exit surface of the patient and the tumor dose derived via
various algorithms—for example Lee et al. [22]. However, it is
often desirable to make intracavitary measurements of absorbed
dose distributions: For example, during external beam treatment
of rectal carcinoma the dose delivered to the rectum and the re-
gion of the anal verge is of critical importance in controlling
deleterious complications [23] and so intracavitary in vivo mea-
surements are indicated. Similarly, intracavitary measurements
during cervical treatments or head and neck treatments would
provide valuable information on the absorbed dose to sensitive
structures such as the bladder and esophagus.
In this paper we describe the design and construction of a
prototype catheter array based on RadFET (radiation sensitive
MOSFETs) and diode detectors—specifically, we describe a
prototype rectal array in which the semiconductors do not have
equal spacing but this is not a limitation of the system.
II. MATERIALS AND METHODS
A. RadFET Detectors
The RadFET detector is a p-type Metal Oxide Field Effect
Transistor (p-MOSFET) that has been optimized as a radiation
detector [24]–[26]. These detectors have excellent radiation-
and physical-characteristics that make them eminently suitable
for use as in vivo radiation detectors in radiotherapy applica-
tions [27]–[30]. Exposure to ionizing radiation, such as gamma
rays, x-rays, electrons and high-energy protons produce a pre-
dictable shift in the threshold voltage (proportional to absorbed
dose) that is easily measurable with a simple circuit that can be
integrated on the same small chip; they can provide real-time
accumulated absorbed-dose information and are thus suited to
use in Intensity Modulated Radiotherapy (IMRT) applications;
as with diodes, they are highly sensitive (approximately 1800
times more sensitive per gamma than an equivalent volume gas-
detector) and are small in size (1 ), they can be operated
in zero-bias mode and typically show a lower over-response
at low-energies than do currently available commercial diodes
[31].
The RadFET used in this work is the ESAPMOS4 device
manufactured by NMRC Cork. This consists of four RadFET
detectors and an integral diode on the same silicon chip. The
chip is 1 mm square and houses two (300/50)
and two (690/15) devices as well as an on-board
diode. The ratios above refer to width/length ratio of the gate
oxide region. The on-board diode has a P+ to N+ minimum dis-
tance of 15 . There are 12 bond-pads in the chip that are used
for making electrical connections. The bond-pad size is 100
square and the distance between bond-pads is 150 . We have
used a 400 nm Implanted Gate Oxide RadFET (IMPL RadFET)
which, because of additional implantation steps, has a lower
initial output voltage than the standard (un-implanted) 400 nm
RadFET. The preirradiation output voltage of 400 nm gate, thick
oxide IMPL RadFET (300/50) is about 1.5 V, whereas the initial
voltage of a standard 400 nm gate, thick oxide RadFET (300/50)
is about 8 V. For 690/15 devices the output voltages are approx.
1 V lover than these.
B. Flip-Chip Bonding
In order to obtain the minimum interconnection complexity
on an array of ten or more RadFETs we have used a process
known as flip-chip bonding [32], [33]. This bonding method
has a lower footprint dimension than other interconnection tech-
niques, such as wire bonding, and removes the need to have
multiple wire bond interconnects that would significantly in-
crease the overall dimensions of the array and possibly cause
radiation shielding difficulties. Flip-chip interconnection uses
conductive bumps to connect the chip to corresponding sub-
strate bond-pads. All packaging is removed and the bare chip
is flipped upside down in order to make the appropriate connec-
tions directly from the chip to the substrate. In this way, it is
only the chip dimensions that determine the final footprint.
There are a number of flip-chip techniques that can be used
in order to make the bond between the chip and the bond-pads.
We have used an anisotropic conductive adhesive to bond the
RadFET to the flexible substrate. To perform this mounting
technique the bond pads of the RadFETs are first coated with 20
high nickel bumps using an electrolyzes plating technique.
We then used Loctite 3441 anisotropically conductive adhesive
to achieve the electrical connection to the substrate. This ma-
terial consists of electrically conductive particles (5-micron di-
ameter gold-coated polymer-spheres) dispersed in an adhesive
matrix at a high concentration to ensure reliable conductivity
between the substrate and the die i.e. electrical interconnection
is in the z-axis direction where particles are trapped between the
bump and track and electrical insulation is maintained in the x-y
plane of the bond interface. In our mounting technique the chip
is bonded under 5 pressure at 200 .
C. Description of the Rectal Array
The array herein described has been constructed specifically
for measuring the dose distribution from the location of the
tumor to the position of the anal verge during external beam ra-
diotherapy treatment of an anal carcinoma. In this construction
we have deliberately used nonuniform detector spacing so that
we can resolve information in the rapidly changing dose area
at the anal verge. All other dimensions of the array have been
chosen so that it is suitable for esophageal, rectal and vaginal
placement. In future developments the external dimensions
will be significantly reduced to permit its use in brachytherapy
catheters.
The array is 12.5 cm in length and consists of ten RadFETs
placed inside a catheter of overall length 53 cm (Fig. 1).
When placed inside the patient, detector 1 (left-most detector
in Fig. 1) will be positioned at the entrance to the anus with de-
tector 10 (right-most detector in Fig. 1) used to monitor the dose
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Fig. 1. Schematic of the rectal array showing the position and spacing of the
individual detectors.
Fig. 2. Schematic cross section of the array showing the rolled flexible
interconnect. In the rectal array, the RadFETs are positioned close to the
surface of the catheter to permit dose measurements at the rectal wall.
at the tumor location. The greatest density of detectors (detec-
tors 1–6) are used to monitor the dose in the anal region, these
detectors have a spacing of 0.6 cm. The following 6 cm have two
detectors (detector 7 & 8) spaced at 3 cm intervals. The final two
detectors (detectors 9 & 10) are placed at 11.5 cm and 12.5 cm.
The detector array has a diameter less than 0.4 cm so it can be
placed in a standard catheter, which is its self filled with tissue
equivalent gel. Markers that can be seen on a portal imager or
x-ray film are placed between detectors 6 and 7 and detectors 9
and 10 to aid in correct placement on the catheter.
The polyimide interconnect substrate consists of a 50 thick
polyimide layer with metal tracks to provide electrical contact
to the RadFET devices. The metal tracks are 70 wide with
a gap of 70 between each track. They consist of a base metal
layer of 5 of copper coated with a 3 layer of nickel and
finally a 0.07 layer of gold. In later developments we intend
to remove this gold layer to reduce any local dose-enhancement
due to photoelectron generation at low energies [34].
Using a 70 track and gap width for the metal tracks and al-
lowing for up to 120 tracks to connect out all I/Os of the RadFET
devices required a substrate width of 1.7 cm—which is signif-
icantly larger than the inner diameter of the catheter. However
because the substrate is flexible we have been able to roll it up
to allow insertion within the catheter. The cross section of the
system is shown schematically in Fig. 2.
Fig. 3 shows the actual prototype constructed array. Clearly
seen are the individual RadFET devices and the 70 tracks
used for electrical connections.
D. Electronic Read-Out
Throughout the work herein discussed, the change in
threshold voltage after irradiation was measured using a PC to
control a Keithley Instruments 2400 source-meter via a Hewlett
Packard GPIB controller card. The system was configured
to measure the gate-source voltage whilst simultaneously
passing a fixed channel current of 10 . In order to reduce
the influence of short-lived interface states, the reader circuit
was programmed to measure the threshold-voltage 10 s after
the initial turn-on of supply current to the RadFET.
Fig. 3. Actual prototype array showing the individual RadFETs flip-chip
mounted on the flexible substrate and the 70 m interconnection lines.
III. RESULTS
Electrical parameters of each RadFET were checked in both
the read and irradiation modes just prior to irradiation in order to
ensure their correct functionality. RadFETs were irradiated with
either 0 V or 5 V present on the gate terminal and all other con-
nections grounded. In the later case the applied potential results
in a 25 MV/cm field across the gate oxide. This field reduces
hole-electron recombination in the and enhances hole-
trapping within the oxide, thereby providing a greater threshold-
voltage shift and thence sensitivity.
A. Radiation Characterization
Initial characterization focused on four aspects of the
individual RadFET performance: 1) Linearity of response
with absorbed dose, 2) determination of the energy-dependent
sensitivity, 3) evaluation of inherent reproducibility and
4) determination of the lower level of detection. Except for
the energy-response analysis, all experimental work was
performed on medical linear accelerators with bremsstrahlung
spectra having end-point energies of 6 or 10 MeV and dose
rates of approximately 6 Gy/min. Data at in a spectrum
was obtained on a medical cobalt machine (dose-rate approxi-
mately 6 Gy/min at reduced source-detector distance). Energy-
response data was obtained using a PANTAK HF-320 constant
potential x-ray generator using ISO narrow spectra at the
Regional Radiation Protection Physics Service, Birmingham,
UK [35].
Device Dose Linearity: In order to measure the linearity of
device response with respect to absorbed radiation dose, Rad-
FETs were individually placed at a depth of 7 cm within a spe-
cially constructed PMMA phantom having a cross section of
30 cm 30 cm and an overall thickness of approximately 20 cm.
These dimensions were chosen to ensure that the devices were
in a region of full charged particle equilibrium and that the influ-
ence of contaminating low-energy radiation scattered from the
linac head was minimized. A calibrated NE2571 Farmer ioniza-
tion chamber (calibration traceable to National standards) was
positioned at the same depth as the RadFETs but displaced by
approximately 2 cm laterally. This horizontal displacement had
previously been determined to be sufficient so that scattered ra-
diation from the graphite thimble had no statistically significant
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Fig. 4. Average response for 20 RadFET devices as a function of increasing
absorbed radiation dose from a 10 MV medical linear accelerator. The solid line
is a linear fit to the data. Statistical r = 0:998.
effect on the response of the RadFET but that the measured ab-
sorbed dose in this location was statistically identical to that at
the location of the RadFET. A calibrated thermometer was sim-
ilarly placed within the phantom to provide accurate tempera-
ture measurement. The Farmer chamber output was measured
using a calibrated Keithley 35 040 therapy electrometer and the
absolute value of the absorbed dose to water was subsequently
derived through the UK standard high-energy photon dosimetry
protocol. Prior to irradiation, the phantom and RadFET were al-
lowed to reach thermal equilibrium. Throughout the experimen-
tation, the phantom temperature was constant to within 1
Fig. 4 shows the device output (voltage-shift) as a function of
total absorbed dose (water) for 5 V biased devices. The data
points represent the mean value observed for 20 RadFETs. Each
device was subjected to increasing absorbed dose—applied in
discrete steps from 0.01 Gy (water) to approximately 50 Gy
(water). The Fig. clearly demonstrates a near linear response
shows up to 50 Gy (water) with for a linear model.
Interdevice Response Variability: Interdevice variability was
examined, using the same experimental set-up as for the lin-
earity tests, for both 0 V and 5 V gate bias, in each case twenty
RadFETs were used. Fig. 5 shows the probability distribution
of sensitivities ( -shift per Gy) for the case of 0 V bias whilst
Fig. 6 shows the distribution for 5 V gate bias. We observed a
statistical of 3% at 0 V and 1% at 5 V gate bias respectively.
Mean absolute sensitivities are 0.0619 and 0.1414 V/Gy at 0 V
and 5 V respectively.
Response Angular Anisotropy: Angular anisotropy was mea-
sured free in-air to avoid changes in optical depth of the device
in the parallelepiped phantom as a function of beam angle. Each
device was held in a low-scatter arm and irradiated to nomi-
nally 0.1 Gy at 15 intervals through 360 . The angle relative
to the machine central axis was measured with a digital incli-
nometer to better than 1 . A fixed Farmer chamber (calibrated
to national standards) provided an independent monitor of the
machine output for normalization purposes. Fig. 7 shows the
in-air anisotropy plot, the data being the mean response of 5-de-
Fig. 5. Interdevice variability in sensitivity at 0 V bias for 20 devices.Mean =
0:0619 V=Gy,  = 3%.
Fig. 6. Interdevice variability in sensitivity at +5 V gate bias. Twenty devices
were irradiated to 0.1 Gy-absorbed dose to water as described in the text. Mean
sensitivity is seen to be 0.1414 V/Gy,  = 1%.
Fig. 7. Angular anisotropy measured with a medical linear accelerator
operating at 6 MV.
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Fig. 8. RadFET energy response (+5 V bias) measured using a PANTAK HF
320 constant potential x-ray generator and ISO narrow spectra—solid line. Also
shown are computed values of the relative energy deposition using MCNPX
(triangles). The response is relative to that in a Co spectrum.
vices. All data are normalized to the response at 0 . Uncertainty
in the plotted data points is 1% at . Anisotropy is 2.5%.
Some distortion is expected due to asymmetric placement of the
RadFET in the catheter.
Response Variation With Photon Energy: The energy re-
sponse of the RadFET ( 5 V gate bias) was measured using the
three different radiation sources described above. High-energy
response data were obtained with the RadFETs mounted
7 cm deep in the PMMA phantom, the actual absorbed dose
to water being determined as for the linearity experiments.
Low-energy response data were obtained with the RadFETs
surface mounted on a thin, ultra low-density expanded polysty-
rene block supplied by RRPPS. This block is used to provide
structural support with very little backscatter thus changes in
the backscatter factor over the energy range of interest had
little effect on the total absorbed dose. Further, since the active
region is only 400 nm thick and has above it only 1.2 of low
Z material, including a silicon nitride passivation region and
beneath it approximately 400 of Si, the device essentially
sees the surface dose. In all cases, absolute dosimetry was
performed by RRPPS and was traceable to national standards.
Fig. 8 shows the observed energy-response at low-energies
(solid line and squares). Also seen on the plot are Monte Carlo
calculated values of energy-deposition (triangles). All data are
relative to the response in a spectrum. Experimental un-
certainty is better than 2% at and calculated and experiment
results match to better than 2%. The relative responses at 6 and
10 MV (not shown) are 1 and 0.99 respectively. An over-re-
sponse of approximately a factor of 6 (relative to ) is ob-
served—this is consistent with results on other commercially
available devices [31] however, in our case, we observe a second
maximum at around 100 keV (both experimentally and compu-
tationally). This is currently under investigation by the authors.
It is likely to be due to secondary photoelectrons from high-Z
materials in the RadFET or substrate construction [36], [37].
B. Monte Carlo Simulated Energy Deposition
In order to quality assure the energy-response data and to pro-
vide future modeling for device optimization purposes we have
built a detailed Monte Carlo simulation model of the RadFET
device using MCNPX [38]. We assume direct proportionality
between the energy deposited in the oxide layer and the physical
response of the device. Although this is clearly an approxima-
tion—especially at very low energies, it is sufficient for our cur-
rent purposes. Calculations proceed, as usual, from the primary
source spectrum. In the case of the low-energy response, we
have used the defined ISO narrow spectra that have been verified
for the RRPS machine used. In the case of the high-energy re-
sponse, the exact spectra are not known experimentally. In these
cases, we have first computed the mixed photon and electron
spectra for the linacs used through detailed Monte Carlo models
using [39] and used this spectrum as the primary
spectrum for the subsequent coupled photon-electron MCNPX
calculations. In all cases we have converged the MCNPX cal-
culations to 1% statistical accuracy, although it is understood
that this is only a partial component of the overall uncertainty
budget for the calculation. In all cases, the energy-deposition
tally was used and passed all statistical tests of sampling and
convergence provided within the MCNPX code.
IV. DISCUSION
Device Linearity: Measurement of device linearity to
absorbed radiation dose has shown that individual RadFETs
follow a sufficiently linear model , at least up to
approximately 50 Gy-absorbed dose (water), to allow simple
determination of absorbed dose via a single calibration factor.
This first-order model becomes increasingly inaccurate at
higher levels of absorbed dose when it is more appropriate to
use an exponential expression [34].
Angular Anisotropy: In-air studies on bare RadFETs reveals
an angular anisotropy of better than 2.5% over 360 . This is ex-
pected to be reduced for the devices encapsulated in the uniform
cylindrical catheter. Providing the orientation of the catheter is
known to within 90 when positioned in the patient, the uncer-
tainty in measured dose due to anisotropy effects will be better
than the maximum 2.5% above. Due to the construction of the
catheter array, it is unlikely that it will twist by more than a few
degrees during insertion, ensuring that the uncertainty due to an-
gular anisotropy is better than 2.5% in practice.
Device Sensitivity: Device sensitivity has been shown to be
0.1414 V/Gy when biased at 5 V. In this mode, we are able to
measure doses lower than 0.05 Gy (water) based on a signal
above noise [40]. This is sufficient to measure doses within the
penumbral region of the radiation beam (defined to be approxi-
mately 20%–80% of the central axis dose [3] of 2 Gy per frac-
tion for a typical external beam treatment) and approximately
0.1 Gy for organs at risk such as the anus, which lie just outside
of the beam.
Interdevice Variability: The variability in sensitivity be-
tween devices is important when considering the calibration of
a multiple detector array. We have measured this variability to
be better than 1% for devices biased at 5 V and 3% when they
are used in passive mode indicating that for all but the most
stringent requirements, a single calibration factor is sufficient
providing that the devices have all been manufactured from the
same wafer.
The precise dimensions and small size of the active region
in a RadFET (the gate), allows the device to be used
for dosimetry in steep dose gradients, as shown by other
researchers [40].
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V. CONCLUSION AND FUTURE WORK
We have developed and constructed a prototype catheter
dosimeter based on MOSFET technology that is suited to
use within natural cavities of the human body. In particular,
we have adapted and utilized an existing MOSFET designed
specifically as a radiation detector—the ESAPMOS4 RadFET
from NMRC Cork. The radiation response characteristics of
individual RadFETs have been shown to be suitable for use as
in vivo dosimeters, i.e. they have small size, require zero or low
voltage bias, can provide a dose measurement with the patient
still in position on the therapy bed and posses dose linearity to
therapeutically high dose levels.
We have successfully demonstrated that these devices can be
used at absorbed dose levels as low as 0.05 Gy, which is suffi-
cient to monitor the dose in regions just outside of the defined
radiation field—i.e. at the anal verge in a rectal treatment.
Within the framework of a 3.5% total uncertainty of dose
measurement, when used with a simple linear response model
the RadFETs used in this work are adequate for single patient
use in a QA program incorporating selective in vivo dosimetry.
The device presented herein is suitable for on-line in vivo
dosimetry for external beam radiotherapy of the rectum, esoph-
agus and vagina. As discussed by other authors [41], MOSFET
dosimeters have an application in the characterization and
quality assurance of the steep dose gradients associated with
the penumbra of modern radiation modalities and we have put
this to good use in the array presented.
Future work involves a detailed analysis of changes in sensi-
tivity with respect to dose-rate, scattered radiation and temper-
ature—although the on-board diode will be used in practice for
temperature compensation.
A patient based trial of the array dosimeter in the treatment
of rectal carcinoma is planned. We are currently in the process
of building a dedicated multichannel RadFET reader and ex-
tending the concept of the array to the use of other semicon-
ductor detectors, such as diodes.
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